HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tissue Extracts

Preparations made from animal tissues or organs (ANIMAL STRUCTURES). They usually contain many components, any one of which may be pharmacologically or physiologically active. Tissue extracts may contain specific, but uncharacterized factors or proteins with specific actions.
Also Known As:
Extracts, Tissue
Networked: 672 relevant articles (10 outcomes, 60 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Schmitt, Manfred: 14 articles (01/2016 - 01/2002)
2. Harbeck, Nadia: 11 articles (11/2010 - 01/2002)
3. Kotzsch, Matthias: 7 articles (01/2017 - 03/2003)
4. Diamandis, Eleftherios P: 7 articles (01/2016 - 05/2002)
5. Brünner, Nils: 7 articles (08/2013 - 01/2002)
6. Magdolen, Viktor: 6 articles (01/2017 - 03/2004)
7. Kiechle, Marion: 6 articles (01/2016 - 08/2002)
8. Foekens, John A: 6 articles (06/2014 - 01/2002)
9. Dorn, Julia: 5 articles (01/2016 - 06/2003)
10. Schmalfeldt, Barbara: 4 articles (01/2016 - 06/2003)

Related Diseases

1. Neoplasms (Cancer)
2. Inflammation (Inflammations)
3. Carcinoma (Carcinomatosis)
4. Fibrosis (Cirrhosis)
09/22/2017 - "Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts ¹H-NMR Spectroscopy."
10/01/1987 - "To determine whether histologic ABs reliably reflect asbestos fiber concentrations in asbestosis, we compared the concentration of ABs in histologic sections to concentrations of ABs and fibers in tissue extracts of 14 asbestos workers with nonspecific interstitial fibrosis. "
08/01/1996 - "Tissue extracts containing DNA repair enzyme, O(6)-methylguanine-DNA methyltransferase, were prepared from liver biopsy samples from 41 patients with cirrhosis (10 viral (HBV and HCV), 17 alcohol and 14 autoimmune), 17 patients with non-cirrhotic diseased liver and 4 patients with histologically normal liver. "
08/01/1996 - "Compared with untreated SHR or WKY, we found the following: (1) Systolic arterial pressure was normalized (P < .025) and LVH completely reversed (P < .025) in SHR, with no significant reduction in systolic arterial pressure or left ventricular mass in WKY; (2) morphometrically determined myocardial fibrosis in SHR was significantly reversed (P < .025) and associated with improved diastolic stiffness (P < .05), which was measured in the isolated heart by calculation of the stiffness constant of the myocardium; no significant changes occurred in WKY; (3) reversal of myocardial fibrosis was accompanied by an increase (P < .025) in myocardial matrix metalloproteinase 1 activity determined by degradation of [14C]collagen with myocardial tissue extracts after trypsin activation of myocardial promatrix metalloproteinase 1; matrix metalloproteinase 1 activity remained unchanged in WKY treated with lisinopril; and (4) systolic dysfunction, measured by a significantly (P < .025) diminished slope of the systolic stress-strain relation under isovolumic conditions of the left ventricle, was found in 110-week-old SHR, and it could be prevented by lisinopril treatment. "
5. Weight Loss (Weight Reduction)

Related Drugs and Biologics

1. Antigens
2. Monoclonal Antibodies
3. Tissue Inhibitor of Metalloproteinase-1
4. Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
5. Matrix Metalloproteinase 1 (Interstitial Collagenase)
6. Peptides (Polypeptides)
7. Fibrin
8. Trypsin
9. Buffers
10. Neoplasm Antigens (Tumor Antigens)

Related Therapies and Procedures

1. Injections
2. Therapeutics
3. Intraperitoneal Injections
4. Subcutaneous Injections
5. Cryosurgery